{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:23:36Z","timestamp":1792484616437,"version":"4.5.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Donor KIR and recipient HLA combinations that minimize inhibition and favor activation of the NK repertoire are associated with improved outcomes after allogeneic hematopoietic cell transplantation (HCT) in patients with myeloid neoplasia. We prospectively evaluated a weighted donor ranking algorithm designed to prioritize HLA-compatible unrelated donors (URDs) with weak inhibitory KIR3DL1\/HLA-Bw4 interaction, followed by donors with nontolerized activating KIR2DS1, and finally those with KIR centromeric B haplotype. During donor evaluation, we performed KIR genotyping and ranked 2079 URDs for 527 subjects with myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). Among all patients, 394 (75%) had at least 1 KIR-advantageous donor, and 263 (50%) underwent HCT. In patients with AML, KIR3DL1 weak inhibition provided protection from relapse. Compared with KIR3DL1-Weak Inhibiting donors, KIR3DL1-Noninteracting donors were associated with increased risk of relapse (HR, 2.97; 95% CI, 1.33-6.64; P = .008) and inferior event-free survival (EFS; HR, 2.14; 95% CI, 1.16-3.95; P = .015). KIR3DL1-Strong Inhibiting donors were associated with HR, 1.65 (95% CI, 0.66-4.08; P = .25) for AML relapse and HR, 1.6 (95% CI, 0.81-3.17; P = .1) for EFS when compared with the use of KIR3DL1-weak inhibiting donors. Donor KIR2DS1\/HLA-C1 status and centromeric KIR haplotype-B content were not associated with decreased risk of AML relapse. There was no benefit to KIR-based donor selection in patients with MDS. This study demonstrates that donor KIR typing is feasible, and prioritization of donors with certain KIR3DL1 genotypes may confer a protection from relapse after HCT in patients with AML.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002701","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T18:42:36Z","timestamp":1618252956000},"page":"2003-2011","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AML"],"prefix":"10.1182","volume":"5","author":[{"given":"Brian C.","family":"Shaffer","sequence":"first","affiliation":[{"name":"Adult Bone Marrow Transplant (BMT) Service, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Internal Medicine, Weill Cornell School of Medicine, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1046-2941","authenticated-orcid":false,"given":"Jean-Benoit","family":"Le Luduec","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"Park","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Devlin","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Epidemiology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Archer","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant (BMT) Service, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9197-2523","authenticated-orcid":false,"given":"Eric","family":"Davis","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant (BMT) Service, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice","family":"Cooper","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant (BMT) Service, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-9985","authenticated-orcid":false,"given":"Melissa","family":"Nhaissi","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant (BMT) Service, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Suri","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant (BMT) Service, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9404-1705","authenticated-orcid":false,"given":"Deborah","family":"Wells","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant (BMT) Service, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Tamari","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant (BMT) Service, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Internal Medicine, Weill Cornell School of Medicine, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant (BMT) Service, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Internal Medicine, Weill Cornell School of Medicine, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann A.","family":"Jakubowski","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant (BMT) Service, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Internal Medicine, Weill Cornell School of Medicine, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant (BMT) Service, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Internal Medicine, Weill Cornell School of Medicine, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine C.","family":"Hsu","sequence":"additional","affiliation":[{"name":"Adult Bone Marrow Transplant (BMT) Service, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Internal Medicine, Weill Cornell School of Medicine, New York, NY; and"},{"name":"Human Oncology and Pathogenesis Program,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"issue":"1","key":"2021041215330694300_B1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V94.1.333.413a31_333_339","article-title":"Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation","volume":"94","author":"Ruggeri","year":"1999","journal-title":"Blood"},{"issue":"9","key":"2021041215330694300_B2","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.4049\/jimmunol.169.9.5118","article-title":"Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets","volume":"169","author":"Hsu","year":"2002","journal-title":"J Immunol"},{"issue":"20","key":"2021041215330694300_B3","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1200\/JCO.2016.70.7059","article-title":"KIR3DL1\/HLA-B subtypes govern acute myelogenous leukemia relapse after hematopoietic cell transplantation","volume":"35","author":"Boudreau","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021041215330694300_B4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/sj.leu.2401982","article-title":"HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse","volume":"15","author":"Wetzler","year":"2001","journal-title":"Leukemia"},{"issue":"14","key":"2021041215330694300_B5","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2010-05-283051","article-title":"Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia","volume":"116","author":"Cooley","year":"2010","journal-title":"Blood"},{"issue":"15","key":"2021041215330694300_B6","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1182\/blood-2009-08-236943","article-title":"Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation","volume":"115","author":"Venstrom","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2021041215330694300_B7","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1182\/blood-2004-12-4825","article-title":"Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes","volume":"105","author":"Hsu","year":"2005","journal-title":"Blood"},{"issue":"8","key":"2021041215330694300_B8","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bbmt.2006.04.008","article-title":"KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy","volume":"12","author":"Hsu","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2021041215330694300_B9","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1182\/blood-2007-01-065383","article-title":"Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT","volume":"109","author":"Miller","year":"2007","journal-title":"Blood"},{"issue":"16","key":"2021041215330694300_B10","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/blood.2019002887","article-title":"External validation of models for KIR2DS1\/KIR3DL1-informed selection of hematopoietic cell donors fails","volume":"135","author":"Schetelig","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2021041215330694300_B11","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1182\/blood-2003-02-0438","article-title":"The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia","volume":"103","author":"Cook","year":"2004","journal-title":"Blood"},{"issue":"9","key":"2021041215330694300_B12","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1056\/NEJMoa1200503","article-title":"HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1","volume":"367","author":"Venstrom","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"2021041215330694300_B13","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.4049\/jimmunol.1302517","article-title":"Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia","volume":"192","author":"Cooley","year":"2014","journal-title":"J Immunol"},{"key":"2021041215330694300_B14","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3389\/fimmu.2019.00734","article-title":"Novel approach to cell surface discrimination between KIR2DL1 subtypes and KIR2DS1 identifies hierarchies in NK repertoire, education, and tolerance","volume":"10","author":"Le Luduec","year":"2019","journal-title":"Front Immunol"},{"issue":"9","key":"2021041215330694300_B15","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.4049\/jimmunol.1202120","article-title":"NK cell tolerance of self-specific activating receptor KIR2DS1 in individuals with cognate HLA-C2 ligand","volume":"190","author":"Pittari","year":"2013","journal-title":"J Immunol"},{"issue":"4","key":"2021041215330694300_B16","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/bloodadvances.2019001053","article-title":"KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation","volume":"4","author":"Weisdorf","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2021041215330694300_B17","doi-asserted-by":"crossref","first-page":"e99543","DOI":"10.1371\/journal.pone.0099543","article-title":"Development of a novel multiplex PCR assay to detect functional subtypes of KIR3DL1 alleles","volume":"9","author":"Boudreau","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"2021041215330694300_B18","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1182\/blood-2005-03-1039","article-title":"Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation","volume":"107","author":"Cook","year":"2006","journal-title":"Blood"},{"issue":"24","key":"2021041215330694300_B19","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"12","key":"2021041215330694300_B20","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood"},{"issue":"3","key":"2021041215330694300_B21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"issue":"2","key":"2021041215330694300_B22","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.immuni.2016.07.005","article-title":"Cell-extrinsic MHC class I molecule engagement augments human NK cell education programmed by cell-intrinsic MHC class I","volume":"45","author":"Boudreau","year":"2016","journal-title":"Immunity"},{"issue":"6","key":"2021041215330694300_B23","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2009-09-245746","article-title":"Education of human natural killer cells by activating killer cell immunoglobulin-like receptors","volume":"115","author":"Fauriat","year":"2010","journal-title":"Blood"},{"issue":"16","key":"2021041215330694300_B24","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2008-09-177055","article-title":"Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation","volume":"113","author":"Yu","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2021041215330694300_B25","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.bbmt.2015.05.002","article-title":"Impact of KIR and HLA genotypes on outcomes after reduced-intensity conditioning hematopoietic cell transplantation","volume":"21","author":"Sobecks","year":"2015","journal-title":"Biol Blood Marrow Transplantation"},{"key":"2021041215330694300_B26","doi-asserted-by":"crossref","first-page":"584520","DOI":"10.3389\/fimmu.2020.584520","article-title":"Haplotype motif-based models for KIR-genotype informed selection of hematopoietic cell donors fail to predict outcome of patients with myelodysplastic syndromes or secondary acute myeloid leukemia","volume":"11","author":"Schetelig","year":"2021","journal-title":"Front Immunol"},{"issue":"22","key":"2021041215330694300_B27","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1182\/blood-2008-12-197467","article-title":"Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity [published correction appears in Blood. 2015;126(10):2266]","volume":"113","author":"Brunstein","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2021041215330694300_B28","first-page":"174","article-title":"The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation","volume":"10","author":"Fedele","year":"2012","journal-title":"Blood Transfus"},{"issue":"1","key":"2021041215330694300_B29","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/j.bbmt.2018.08.022","article-title":"KIR donor selection: feasibility in identifying better donors","volume":"25","author":"Weisdorf","year":"2019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/7\/2003\/1804806\/advancesadv2020002701.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/7\/2003\/1804806\/advancesadv2020002701.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T18:45:17Z","timestamp":1618253117000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/7\/2003\/475686\/Prospective-KIR-genotype-evaluation-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,12]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,4,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002701","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,12]]}}}